The pharmaceutical-derived AhR agonists identified in the screening study [54], including flutamide, leflunomide, mexiletine hydrochloride, nimodipine, omeprazole, sulindac and tranilast were investigated in breast cancer cells. Here, AHR is linked to breast carcinoma.